ImmunityBio Is Burning $309 Million a Year While the FDA Calls Its Drug Claims Misleading

NEW YORK, April 3 —

The FDA doesn't use the word "misleading" casually. When the agency issued an enforcement action against ImmunityBio's promotional materials for ANKTIVA, its approved bladder cancer therapy, it did so because the company's own marketing overstated what the drug can do. This happened during the same week ImmunityBio rushed out a press release confirming "statistical power" in its BCG-naïve trial, a textbook distraction play. For a stock trading at 60x trailing revenue with $309 million in annual cash burn, the question isn't whether ANKTIVA works. It's whether the company selling it can be trusted to tell you the truth about how well it's working.

What the Street Believes

Wall Street consensus has IBRX at $14.80, implying 102% upside from today's $7.30. The bull case is straightforward: ANKTIVA is a first-mover in BCG-unresponsive non-muscle-invasive bladder cancer, revenue grew roughly 407% year-over-year to $113 million, and the company just picked up a Macau approval that opens the door to greater China. The NCCN expanded its guidelines to include ANKTIVA, which in oncology is the equivalent of getting your restaurant into the Michelin guide. Analysts model this as an inflection story where revenue growth eventually overwhelms the burn rate.

Here's the problem with that thesis: the FDA just told you the company is exaggerating ANKTIVA's commercial story. Not a competitor. Not a short seller. The Food and Drug Administration itself reviewed ImmunityBio's promotional materials and concluded they were misleading. If the regulator responsible for approving this drug thinks management is overselling it, what does that tell you about the adoption curve baked into a $14.80 price target?

What the Data Actually Shows

Start with the dilution. ImmunityBio's share count grew 31.3% year-over-year. That means if you owned 1% of the company twelve months ago, you now own about 0.76%. Revenue grew faster in percentage terms, sure. But revenue is $113 million and the company burned $309 million in free cash flow. Simple subtraction: ImmunityBio needs to raise roughly $196 million per year beyond what it earns just to keep the lights on. That money comes from somewhere, and that somewhere is your ownership stake.

"The promotional materials for ANKTIVA are misleading because they make representations or suggestions about the efficacy of ANKTIVA that are not supported by substantial evidence or substantial clinical experience." — FDA enforcement action regarding ImmunityBio's ANKTIVA promotion

Read that language carefully. The FDA isn't saying ImmunityBio made a typo in a brochure. It's saying the company made claims about how well ANKTIVA works that aren't backed by the evidence. For a drug in its commercial launch phase, this is poison. Oncologists making prescribing decisions read these enforcement actions. Hospital formulary committees read them. Payers building coverage policies read them. The FDA essentially told the entire healthcare system: be skeptical of what this company says about its own drug.

Now look at the timing. Within the same week as the FDA warning, ImmunityBio issued a press release confirming "statistical power" in its BCG-naïve pivotal trial. Statistical power is not a result. It's a statement that the trial has enough patients enrolled to potentially detect a difference. This is like a restaurant announcing it has enough tables to seat customers. It tells you nothing about whether people are actually showing up to eat. The press release was a noise machine designed to drown out the FDA signal.

The earnings history confirms the pattern. ImmunityBio missed EPS estimates by 7.1% two quarters ago, matched estimates the following quarter, then beat by 30% most recently. That beat sounds impressive until you realize "beating" meant losing $0.07 per share instead of the expected $0.10 loss. The company has never posted a profitable quarter. At negative 365x forward earnings, the stock isn't priced on what ImmunityBio earns. It's priced on faith.

Why This Changes Everything

The math for existing IBRX shareholders is brutal. At 31% annual dilution, your per-share claim on the business halves roughly every 2.5 years. For the stock to simply stay flat at $7.30, the company's total enterprise value needs to grow at 31% annually just to offset the new shares flooding the market. That requires revenue to not only grow but accelerate, which brings us back to the FDA problem.

If the misleading-promotion flag slows ANKTIVA's adoption curve by even 15-20%, the consensus revenue estimates for 2027 fall apart. Analysts currently model something north of $300 million. Knock that down to $250 million because oncologists grow cautious, and you've got a company still burning cash, still diluting, and now missing the growth targets that justify a $6.7 billion market cap. At 20x a more realistic $250 million revenue estimate, the equity value is $5 billion. Divide that by a share count that's 31% larger and you get a stock price closer to $4.50. That's 38% below today.

The specific catalyst to watch is the next two quarterly revenue prints. If ANKTIVA prescriptions are decelerating relative to the launch curve, the FDA warning did real damage. If they're accelerating, the Street will forgive everything. There is no middle ground at this valuation.

The Bull Case

The strongest argument for IBRX is that FDA promotional warnings are common in biotech and almost never derail a successful drug. Keytruda, Opdivo, and dozens of blockbusters have received similar letters without any lasting commercial impact. If ANKTIVA genuinely works better than the alternatives for BCG-unresponsive bladder cancer, oncologists will prescribe it regardless of what the FDA says about a marketing brochure. The 99.3% gross margin means every incremental dollar of revenue drops almost entirely to the bottom line, so the company doesn't need to grow revenue much past $400 million to reach cash-flow breakeven.

The Macau approval and NCCN guideline inclusion are real catalysts. International expansion could eventually double the addressable market. And the BCG-naïve trial, if successful, would more than triple the eligible patient population.

These are legitimate points. But they require you to trust management's characterization of ANKTIVA's trajectory at the exact moment the FDA is telling you that characterization is misleading. That's a big ask. And they require you to ignore the dilution math, which doesn't care about clinical data. Every quarter that ImmunityBio burns more cash than it earns, your slice of the pie gets smaller. A great drug in a bad capital structure is still a bad investment for common shareholders.

The Bottom Line

ImmunityBio is asking you to pay 60x revenue for a company whose own regulator says it's exaggerating its drug's commercial story. The 31% annual dilution means you need the stock to appreciate by a third every year just to break even on a per-share basis. ANKTIVA might be a good drug. It might even be a great drug. But at $7.30 per share with this burn rate and this credibility gap, existing shareholders are funding the company's survival while their ownership gets shredded. The stock is a show-me story trading at a trust-me price. I'd want to see two consecutive quarters of revenue acceleration and a clear path to cash-flow breakeven before touching it. Run the free ImmunityBio, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

What did the FDA say about ImmunityBio's ANKTIVA promotion?

The FDA issued an enforcement action stating that ImmunityBio's promotional materials for ANKTIVA were "misleading" because they made efficacy claims not supported by substantial evidence or clinical experience. This is a formal regulatory flag, not a routine paperwork issue, and it signals that the company may be overstating ANKTIVA's commercial potential to investors and prescribers.

How much is ImmunityBio diluting shareholders?

ImmunityBio's share count grew 31.3% year-over-year. The company burned $309 million in free cash flow against only $113 million in revenue, meaning it must continually raise outside capital to fund operations. At this rate, a shareholder's ownership stake roughly halves every 2.5 years unless the company reaches cash-flow breakeven.

Why is IBRX stock down 35% since its last earnings report?

The decline reflects a combination of factors: the FDA misleading-promotion warning shook confidence in the ANKTIVA launch narrative, the company continues to post significant net losses despite revenue growth, and ongoing dilution from capital raises weighs on per-share value. The stock dropped from roughly $11 to $7.30 as investors reassessed the gap between management's optimistic framing and the regulatory reality.

What would need to happen for IBRX stock to reach the $14.80 consensus price target?

ANKTIVA would need to accelerate its commercial adoption despite the FDA warning, the BCG-naïve pivotal trial would need positive results to triple the addressable patient population, and the company would need a credible path to cash-flow breakeven that slows dilution. Missing on any of these fronts makes the $14.80 target, which implies a $13-plus billion market cap on a diluted basis, very difficult to justify.

Is the ImmunityBio BCG-naïve trial announcement significant?

Less than it sounds. The company confirmed "statistical power," which means the trial has enough enrolled patients to potentially detect a meaningful difference between ANKTIVA plus BCG versus BCG alone. This is a milestone for trial design, not a clinical result. Actual efficacy data is still months away. The timing of the announcement, the same week as the FDA warning, suggests it was designed to redirect investor attention.